scholarly journals Micronized Palmitoylethanolamide Reduces the Symptoms of Neuropathic Pain in Diabetic Patients

2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Chiara Schifilliti ◽  
Lelio Cucinotta ◽  
Viviana Fedele ◽  
Carmela Ingegnosi ◽  
Salvatore Luca ◽  
...  
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Symptom Score ◽  
Acid Amide ◽  
Screening Instrument ◽  
Total Symptom Score ◽  
Diabetic Patients ◽  
Serious Adverse Events ◽  
Michigan Neuropathy Screening Instrument ◽  
Pain Symptoms

The present study evaluated the effectiveness of micronized palmitoylethanolamide (PEA-m) treatment in reducing the painful symptoms experienced by diabetic patients with peripheral neuropathy. PEA-m, a fatty acid amide of the N-acylethanolamine family, was administered (300 mg twice daily) to 30 diabetic patients suffering from painful diabetic neuropathy. Before treatment start, after 30 and 60 days the following parameters were assessed: painful symptoms of diabetic peripheral neuropathy using the Michigan Neuropathy Screening instrument; intensity of symptoms characteristic of diabetic neuropathic pain by the Total Symptom Score; and intensity of different subcategories of neuropathic pain by the Neuropathic Pain Symptoms Inventory. Hematological and blood chemistry tests to evaluate metabolic control and safety were also performed. Statistical analysis (ANOVA) indicated a highly significant reduction in pain severity (P<0.0001) and related symptoms (P<0.0001) evaluated by Michigan Neuropathy Screening instrument, Total Symptom Score, and Neuropathic Pain Symptoms Inventory. Hematological and urine analyses did not reveal any alterations associated with PEA-m treatment, and no serious adverse events were reported. These results suggest that PEA-m could be considered as a promising and well-tolerated new treatment for symptomatology experienced by diabetic patients suffering from peripheral neuropathy.

scholarly journals Comparison of Efficiencies of Michigan Neuropathy Screening Instrument, Neurothesiometer, and Electromyography for Diagnosis of Diabetic Neuropathy

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Turkan Mete ◽  
Yusuf Aydin ◽  
Mustafa Saka ◽  
Halise Cinar Yavuz ◽  
Sule Bilen ◽  
...  
Keyword(s):  
Peripheral Neuropathy ◽  
Physical Examination ◽  
Diabetic Peripheral Neuropathy ◽  
Diabetes Type 2 ◽  
Screening Instrument ◽  
Diabetes Type ◽  
Diabetic Patients ◽  
Patients With Diabetes ◽  
Michigan Neuropathy Screening Instrument

Aim. This study compares the effectiveness of Michigan Neuropathy Screening Instrument (MNSI), neurothesiometer, and electromyography (EMG) in detecting diabetic peripheral neuropathy in patients with diabetes type 2.Materials and Methods. 106 patients with diabetes type 2 treated at the outpatient clinic of Ankara Numune Education and Research Hospital Department of Endocrinology between September 2008 and May 2009 were included in this study. Patients were evaluated by glycemic regulation tests, MNSI (questionnaire and physical examination), EMG (for detecting sensorial and motor defects in right median, ulnar, posterior tibial, and bilateral sural nerves), and neurothesiometer (for detecting alterations in cold and warm sensations as well as vibratory sensations).Results. According to the MNSI score, there was diabetic peripheral neuropathy in 34 (32.1%) patients (score ≥2.5). However, when the patients were evaluated by EMG and neurothesiometer, neurological impairments were detected in 49 (46.2%) and 79 (74.5%) patients, respectively.Conclusion. According to our findings, questionnaires and physical examination often present lower diabetic peripheral neuropathy prevalence. Hence, we recommend that in the evaluation of diabetic patients neurological tests should be used for more accurate results and thus early treatment options to prevent neuropathic complications.

scholarly journals Diabetic Peripheral Neuropathy: Epidemiology, Physiopathology, Diagnosis and Treatment

2019 ◽  
Vol 7 (1) ◽  
pp. 35-48
Author(s):  
Nazma Akter
Keyword(s):  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Diabetic Peripheral Neuropathy ◽  
Clinical Evidence ◽  
Current Treatment ◽  
Diabetic Patients ◽  
First Line ◽  
Diabetic Neuropathic Pain ◽  
Current Treatment Regimen ◽  
Limb Proprioception

Diabetic peripheral neuropathy (DPN) is a common complication of both type 1 and type 2 diabetes. It affects over 90% of the diabetic patients. It is widely accepted that the toxic effects of hyperglycemia play an important role in the development of this complication, but several other hypotheses have been postulated. It is typically characterized by significant deficits in tactile sensitivity, vibration sense, lower-limb proprioception, and kinesthesia. Painful DPN has been shown to be associated with significant reductions in overall quality of life, increased levels of anxiety and depression, sleep impairment, and greater gait variability. DPN is often misdiagnosed and inadequately treated. Clinical recognition of DPN is imperative for allowing timely symptom management to reduce the morbidity associated with this condition. The management of diabetic neuropathic pain consists basically in excluding other causes of painful peripheral neuropathy, improving glycemic control as a prophylactic therapy and using medications to alleviate pain. First line drugs for pain relief include anticonvulsants, such as pregabalin and gabapentin and antidepressants, especially those that act to inhibit the reuptake of serotonin and noradrenaline. In addition, there is experimental and clinical evidence that opioids can be helpful in pain control, mainly if associated with first line drugs. Other agents, including for topical application, such as capsaicin cream and lidocaine patches, have also been proposed to be useful as adjuvant in the control of diabetic neuropathic pain, but the clinical evidence is insufficient to support their use. The purpose of this review is to examine proposed mechanisms of DPN, summarize current treatment regimen. A better understanding of the mechanisms underlying diabetic neuropathic pain will contribute to the search of new therapies. Delta Med Col J. Jan 2019 7(1): 35-48

Age Differences in Hopelessness and Toe Pain in Persons with Insulin-Dependent and Non-Insulin-Dependent Diabetes Mellitus

2010 ◽  
Vol 100 (6) ◽  
pp. 445-451 ◽  
Author(s):  
Stephen Morewitz ◽  
Najwa Javed ◽  
Sharada Tata ◽  
Joel Clark
Keyword(s):  
Depressive Symptoms ◽  
Peripheral Neuropathy ◽  
Age Differences ◽  
Null Hypothesis ◽  
Large Population ◽  
Dependent Diabetes Mellitus ◽  
Diabetic Patients ◽  
Insulin Dependent ◽  
Pain Symptoms ◽  
Insulin Dependent Diabetic

Background: Several studies have established an association between diabetic neuropathy and depressive symptoms. There is a link between depression and peripheral neuropathy in diabetic patients, suggesting an increased likelihood that diabetic patients will experience depressive symptoms related to lower-extremity peripheral neuropathy and arthritis during middle age and later life. The goal of this investigation was to determine whether there are age differences between insulin-dependent and non-insulin-dependent diabetic patients regarding their feelings of hopelessness and toe pain. Methods: A large population-based sample of 32,006 adults from the 1998 National Health Interview Survey was analyzed with multivariate statistical procedures. We performed χ2 and correlation procedures to test the null hypothesis that there are no age or sex differences between insulin-dependent and non-insulin-dependent diabetic patients in their reporting of feelings of hopelessness and toe pain symptoms in the previous 12 months. Results: There were significant differences between age and sex groups of insulin-dependent and non-insulin-dependent diabetic patients in reporting feelings of hopelessness and toe pain symptoms, rejecting the null hypothesis. Correlational analysis conducted between the variables of hopelessness and toe pain yielded significant correlations in insulin-dependent (r = .28; P = .0009; α = .05), and non-insulin-dependent (r = 0.19; P = .001; α = .05) women older than 61 years, concluding that diabetic women are more likely to experience hopelessness and toe pain in that age group regardless of insulin status. Conclusions: Clinicians should incorporate depression and toe pain symptoms into their assessment and treatment, especially in diabetic women older than 61 years. (J Am Podiatr Med Assoc 100(6): 445–451, 2010)

scholarly journals Prevalence of Peripheral Neuropathic Pain among Adult Diabetic Patients (T2DM) with Peripheral Neuropathy and Quality of Life of the Patients with Peripheral Neuropathic Pain

2020 ◽  
Author(s):  
Jawad Ahmad Abu-Shennar ◽  
Nurhan Bayraktar ◽  
Hatic Bebis
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Rating Scale ◽  
Assessment Tool ◽  
Study Data ◽  
Diabetic Patients ◽  
Life Questionnaire ◽  
Peripheral Neuropathic Pain

Abstract Aim The aim of the study was to assess the prevalence of diabetic peripheral neuropathic pain (DPNP) among adult patients suffering from type 2 diabetes mellitus (T2DM) with diabetic peripheral neuropathy (DPN) as well as to determine the quality of life of patients with DPNP.Materials and method The study designed in cross-sectional research model was conducted at the Jordanian Ministry of Health in Jordan, Amman during the period from 15 June 2019 to 5 October 2019. A total of 400 adult T2DM patients with DNP were recruited for the study. Data were collected by way of an assessment tool package, including descriptive data (demographics, anthropometric measurements, laboratory measurements, and clinical data), the Douleur Neuropathique4 (DN4) questionnaire, physical exam, Quality of Life Questionnaire (EQ-5D), and Numeric Pain Rating Scale (NRS). To analyze study data descriptive and inferential statistics were used.Results Results of the current study showed that the prevalence of DPNP among adult T2DM patients with DPN was high (47.8%). About half of the participants had mild or moderate pain with the most frequently reported symptoms of tingling and burning. Uncontrolled diabetes was found to be the main predictor of DPNP among patients with DPN. Participants who had DPNP reported having problems in connection with mobility, self-care, routine activities, discomfort, and anxiety or/and depression, and they had a significantly lower quality of life with poorer self-rated health status than those without DPNP. Besides, the effect of pain on their quality of life was found to be significant.Conclusion The study recommends, in accordance with the results, that strategies should be developed for an effective management of painful DPN with an integrated and interdisciplinary approach. Current clinical guideline recommendations should be followed to improve patient care and reduce the burden of the disease.

scholarly journals Prevalence of Peripheral Neuropathic Pain among Adult Diabetic Patients (T2DM) with Peripheral Neuropathy and Quality of Life of the Patients with Peripheral Neuropathic Pain

2020 ◽  
Author(s):  
Jawad Ahmad Abu-Shennar ◽  
Nurhan Bayraktar ◽  
Hatice Bebis
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Rating Scale ◽  
Assessment Tool ◽  
Study Data ◽  
Diabetic Patients ◽  
Life Questionnaire ◽  
Peripheral Neuropathic Pain

Abstract Aim: The aim of the study was to assess the prevalence of diabetic peripheral neuropathic pain (DPNP) among adult patients suffering from type 2 diabetes mellitus (T2DM) with diabetic peripheral neuropathy (DPN) as well as to determine the quality of life of patients with DPNP.Materials and method: The study designed in cross-sectional research model was conducted at the Jordanian Ministry of Health in Jordan, Amman during the period from 15 June 2019 to 5 October 2019. A total of 400 adult T2DM patients with DNP were recruited for the study. Data were collected by way of an assessment tool package, including descriptive data (demographics, anthropometric measurements, laboratory measurements, and clinical data), the Douleur Neuropathique4 (DN4) questionnaire, physical exam, Quality of Life Questionnaire (EQ-5D), and Numeric Pain Rating Scale (NRS). To analyze study data descriptive and inferential statistics were used. Results: Results of the current study showed that the prevalence of DPNP among adult T2DM patients with DPN was high (47.8%). About half of the participants had mild or moderate pain with the most frequently reported symptoms of tingling and burning. Uncontrolled diabetes was found to be the main predictor of DPNP among patients with DPN. Participants who had DPNP reported having problems in connection with mobility, self-care, routine activities, discomfort, and anxiety or/and depression, and they had a significantly lower quality of life with poorer self-rated health status than those without DPNP. Besides, the effect of pain on their quality of life was found to be significant. Conclusion: The study recommends, in accordance with the results, that strategies should be developed for an effective management of painful DPN with an integrated and interdisciplinary approach. Current clinical guideline recommendations should be followed to improve patient care and reduce the burden of the disease.

scholarly journals Prevalence of Peripheral Neuropathic Pain among Adult Diabetic Patients (T2DM) with Peripheral Neuropathy and Quality of Life of the Patients with Peripheral Neuropathic Pain

2020 ◽  
Author(s):  
Jawad Ahmad Abu-Shennar ◽  
Nurhan Bayraktar ◽  
Hatic Bebis
Keyword(s):  
Quality Of Life ◽  
Neuropathic Pain ◽  
Peripheral Neuropathy ◽  
Rating Scale ◽  
Assessment Tool ◽  
Study Data ◽  
Diabetic Patients ◽  
Life Questionnaire ◽  
Peripheral Neuropathic Pain

Abstract Aim The aim of the study was to assess the prevalence of diabetic peripheral neuropathic pain (DPNP) among adult patients suffering from type 2 diabetes mellitus (T2DM) with diabetic peripheral neuropathy (DPN) as well as to determine the quality of life of patients with DPNP.Materials and method The study designed in cross-sectional research model was conducted at the Jordanian Ministry of Health in Jordan, Amman during the period from 15 June 2019 to 5 October 2019. A total of 400 adult T2DM patients with DNP were recruited for the study. Data were collected by way of an assessment tool package, including descriptive data (demographics, anthropometric measurements, laboratory measurements, and clinical data), the Douleur Neuropathique4 (DN4) questionnaire, physical exam, Quality of Life Questionnaire (EQ-5D), and Numeric Pain Rating Scale (NRS). To analyze study data descriptive and inferential statistics were used.Results Results of the current study showed that the prevalence of DPNP among adult T2DM patients with DPN was high (47.8%). About half of the participants had mild or moderate pain with the most frequently reported symptoms of tingling and burning. Uncontrolled diabetes was found to be the main predictor of DPNP among patients with DPN. Participants who had DPNP reported having problems in connection with mobility, self-care, routine activities, discomfort, and anxiety or/and depression, and they had a significantly lower quality of life with poorer self-rated health status than those without DPNP. Besides, the effect of pain on their quality of life was found to be significant.Conclusion The study recommends, in accordance with the results, that strategies should be developed for an effective management of painful DPN with an integrated and interdisciplinary approach. Current clinical guideline recommendations should be followed to improve patient care and reduce the burden of the disease.

Sign in / Sign up

Export Citation Format

Share Document